Acusphere, Inc.
Biotech Specialty Pharma
500 Arsenal Street
Watertown, MA 02472 USA
phone: 617.648.8800
fax: 617-926-4750
Symbol ACUS
Exchange NASDAQ
Founded 0
Employees
www.acusphere.com
Research Sector Biotech Specialty Pharma
Summary Description
New drugs and improved formulations of existing drugs using proprietary porous microparticle technology.
Management
Frank Baldino, Jr., Ph.D., has served as one of our directors; Garen Bohlin, has served as one of our directors; Sandra L. Fenwick, has served as one of our directors; Martyn Greenacre, has served as one of our directors; Derek Lemke-von Ammon, has served as a director of the Company; Sherri C. Oberg, a co-founder of Acusphere, has served as our President and Chief Executive Officer; Mr. Bohlin, Ms. Fenwick and Mr. Greenacre, Audit Committee members;Dr. Baldino, Ms. Fenwick and Mr. Lemke-von Ammon, Compensation Committee members; Mr. Bohlin, Mr. Greenacre and Mr. Lemke-von Ammon, Nominating and Corporate Governance Committee members; Sherri C. Oberg, a co-founder of Acusphere; Howard Bernstein, M.D., Ph.D., has served as our Senior Vice President; Michael R. Slater, has served as our Senior Vice President; John F. Thero, has served as our Senior Vice President; Richard Walovitch, Ph.D, has served as our Senior Vice President; Mona Haynes, has served as our Vice President
Ownership
Financials Mkt Cap :123


* numbers in thousands

 
Keywords
microparticle, porous particle, red blood cells, intravenous, inhallation

Comment | Printable Version | Jun. 24, 2008
If you work for Acusphere, Inc. and want to update this profile, click here

Description
Acusphere, Inc. develops new drugs and improved formulations of existing drugs using its proprietary porous microparticle technology. The Company is focused on developing proprietary drugs that can offer significant benefits such as improved safety and efficacy, increased patient compliance, greater ease of use, expanded indications or reduced cost.
Products / Services
AI-128, First Clinical-Stage Product Candidate from their Pulmonary Drug Delivery System, PDDS. AI-700, Intravenous Delivery of Gas for Ultrasound Contrast. AI-850, First Clinical-Stage Product Candidate from their Hydrophobic Drug Delivery System, HDDS. Hydrophobic drugs, which are drugs that do not dissolve well in water, are often difficult to formulate, especially for intravenous delivery.
Technology / Differentiation
Three initial product candidates were created using technology that controls the size and porosity of microparticles in a versatile manner, so microparticles are customized to address the delivery needs of a variety of drugs. The Company is focused on creating porous microparticles that are smaller than red blood cells, which are important for delivering drugs intravenously so that they can pass through the body's smallest blood vessels, allowing the drug to dissolve more rapidly, and to the lung via inhalation.
Market / Customers
The Company's three initial product candidates are in clinical development and are designed to address large unmet clinical needs within cardiology, oncology and asthma.


2008-11-12-335